Clinical trial
A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT06332755 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Lead sponsor
- LG Chem
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- June 5, 2024
- Completion date
- March 31, 2028
- Enrollment
- 76 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck squamous cell carcinoma(hnscc), malignant melanoma, non-small cell lung cancer(nsclc), renal cell carcinoma(rcc), urothelial carcinoma